Plasma procurement and plasma product safety in light of the COVID‐19 pandemic from the perspective of the plasma industry
Open Access
- 17 March 2022
- journal article
- review article
- Published by Wiley in Vox Sanguinis
- Vol. 117 (6) , 780-788
Abstract
This review, written from the perspective of the plasma industry, discusses plasma procurement and plasma product safety in light of the COVID‐19 pandemic. The COVID‐19 pandemic impacted the whole world and, therefore, not unexpectedly, the pharmaceutical industry too. In spite of this, the plasma protein industry has continued to provide life saving therapies to critically ill patients. Moreover, companies have collected COVID convalescent plasma (CP) to support development of investigational therapies, for example, hyperimmune globulins to potentially treat SARS‐CoV‐2 infection, and collaborated with those collecting COVID CP for direct transfusion, which has been made available under emergency use in the United States. For plasma that is fractionated to become a therapy, general knowledge of coronaviruses and numerous new studies on the structure and function of SARS‐CoV‐2 provide reassurance that existing industry precautions, including donor selection, as well as virus inactivation and removal steps during the manufacturing process are sufficient to maintain the high standards of virus safety of plasma products. The pandemic also revealed the vulnerability and inadequacy of the current plasma ecosystem. There is a need for more plasma to be collected around the world to meet the growing need for safe and efficacious plasma‐derived therapies. This requires outdated regulatory and policy restrictions to be realigned with current scientific evidence. More countries around the world should be in a position to contribute to global supply of plasma so that patients with life‐threatening conditions ‐ and often no alternative therapeutic solutions ‐ have better access to care.Keywords
This publication has 59 references indexed in Scilit:
- Discovery of Seven Novel Mammalian and Avian Coronaviruses in the Genus Deltacoronavirus Supports Bat Coronaviruses as the Gene Source of Alphacoronavirus and Betacoronavirus and Avian Coronaviruses as the Gene Source of Gammacoronavirus and DeltacoronavirusJournal of Virology, 2012
- How much blood is needed?Vox Sanguinis, 2010
- Cytokines and plasma factors in sickle cell diseaseCurrent Opinion in Hematology, 2007
- Shortage of human intravenous immunoglobulin—reasons and possible solutionsNature Clinical Practice Neurology, 2007
- Community Blood Supply Model: Development of a New Model to Assess the Safety, Sufficiency, and Cost of the Blood SupplyMedical Decision Making, 2005
- West Nile Virus among Blood Donors in the United States, 2003 and 2004New England Journal of Medicine, 2005
- Heat sensitivity of a SARS‐associated coronavirus introduced into plasma productsVox Sanguinis, 2004
- Koch's postulates fulfilled for SARS virusNature, 2003
- Effect of pH and temperature on the infectivity of human coronavirus 229ECanadian Journal of Microbiology, 1989
- Studies With Human Coronaviruses II. Some Properties of Strains 229E and OC43Experimental Biology and Medicine, 1972